Excessive ATP hydrolysis in ischemic myocardium by mitochondrial F1F0-ATPase: effect of selective pharmacological inhibition of mitochondrial ATPase hydrolase activity.

@article{Grover2004ExcessiveAH,
  title={Excessive ATP hydrolysis in ischemic myocardium by mitochondrial F1F0-ATPase: effect of selective pharmacological inhibition of mitochondrial ATPase hydrolase activity.},
  author={Gary James Grover and Karnail S. Atwal and Paul G. Sleph and Feng-li Wang and Hossain Monshizadegan and Thomas M. Monticello and David William Green},
  journal={American journal of physiology. Heart and circulatory physiology},
  year={2004},
  volume={287 4},
  pages={
          H1747-55
        }
}
Mitochondrial F(1)F(0)-ATPase normally synthesizes ATP in the heart, but under ischemic conditions this enzyme paradoxically causes ATP hydrolysis. Nonselective inhibitors of this enzyme (aurovertin, oligomycin) inhibit ATP synthesis in normal tissue but also inhibit ATP hydrolysis in ischemic myocardium. We characterized the profile of aurovertin and oligomycin in ischemic and nonischemic rat myocardium and compared this with the profile of BMS-199264, which only inhibits F(1)F(0)-ATP… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 55 CITATIONS, ESTIMATED 48% COVERAGE

ATP synthase and the actions of inhibitors utilized to study its roles in human health, disease, and other scientific areas.

  • Microbiology and molecular biology reviews : MMBR
  • 2008
VIEW 13 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

SEURAT-1 liver gold reference compounds: a mechanism-based review

  • Archives of Toxicology
  • 2014
VIEW 19 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

FILTER CITATIONS BY YEAR

2007
2019

CITATION STATISTICS

  • 8 Highly Influenced Citations

References

Publications referenced by this paper.
SHOWING 1-10 OF 32 REFERENCES

Cardioprotective effects of the ATP-sensitive potassium channel opener BMS-180448: functional and energetic considerations

GJ Grover, S Dzwonczyk, PG Sleph, H Malone, RA. Behling
  • J Cardiovasc Pharmacol
  • 1997
VIEW 3 EXCERPTS